Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor.

Dickinson PA, Cantarini MV, Collier J, Frewer P, Martin S, Pickup K, Ballard P.

Drug Metab Dispos. 2016 Aug;44(8):1201-12. doi: 10.1124/dmd.115.069203. Epub 2016 May 25.

PMID:
27226351
2.

(18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors.

Desar IM, Gilles R, van Herpen CM, Timmer-Bonte AJ, Cantarini MV, van der Graaf WT, Oyen WJ.

World J Nucl Med. 2012 May;11(2):65-9. doi: 10.4103/1450-1147.103413.

3.

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.

Banerji U, Camidge DR, Verheul HM, Agarwal R, Sarker D, Kaye SB, Desar IM, Timmer-Bonte JN, Eckhardt SG, Lewis KD, Brown KH, Cantarini MV, Morris C, George SM, Smith PD, van Herpen CM.

Clin Cancer Res. 2010 Mar 1;16(5):1613-23. doi: 10.1158/1078-0432.CCR-09-2483. Epub 2010 Feb 23.

4.

Circulating tumour-derived predictive biomarkers in oncology.

Hodgson DR, Wellings R, Orr MC, McCormack R, Malone M, Board RE, Cantarini MV.

Drug Discov Today. 2010 Feb;15(3-4):98-101. doi: 10.1016/j.drudis.2009.12.006. Epub 2010 Jan 4. Review.

PMID:
20045486
5.

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.

Board RE, Ellison G, Orr MC, Kemsley KR, McWalter G, Blockley LY, Dearden SP, Morris C, Ranson M, Cantarini MV, Dive C, Hughes A.

Br J Cancer. 2009 Nov 17;101(10):1724-30. doi: 10.1038/sj.bjc.6605371. Epub 2009 Oct 27.

6.

Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours.

Desar IM, Bovenschen HJ, Timmer-Bonte AJ, Cantarini MV, Van Der Graaf WT, Van Rossum MM, Van Herpen CM.

Acta Oncol. 2010;49(1):110-3. doi: 10.3109/02841860903104152. No abstract available.

PMID:
19634052
7.

Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib?

Wilson CG, O'Mahony B, Connolly SM, Cantarini MV, Farmer MR, Dickinson PA, Smith RP, Swaisland HC.

Int J Pharm. 2009 Jul 6;376(1-2):7-12. doi: 10.1016/j.ijpharm.2009.04.008. Epub 2009 Apr 14.

PMID:
19497691
8.

The relative bioavailability of gefitinib administered by granular formulation.

Cantarini MV, Bailey CJ, Collins B, Smith RP.

Cancer Chemother Pharmacol. 2008 Jul;62(2):203-8. Epub 2007 Oct 2.

PMID:
17909808
9.

Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors.

Bergman E, Forsell P, Persson EM, Knutson L, Dickinson P, Smith R, Swaisland H, Farmer MR, Cantarini MV, Lennernäs H.

Int J Pharm. 2007 Aug 16;341(1-2):134-42. Epub 2007 Apr 6.

PMID:
17482782
10.

Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.

Swaisland HC, Cantarini MV, Fuhr R, Holt A.

Clin Pharmacokinet. 2006;45(6):633-44.

PMID:
16719544
11.

A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers.

Cantarini MV, Macpherson MP, Marshall AL, Robinson AV, Bailey CJ.

Cancer Chemother Pharmacol. 2005 Dec;56(6):557-62. Epub 2005 Jul 23.

PMID:
16041611
13.

Effect of oral linezolid on the pressor response to intravenous tyramine.

Cantarini MV, Painter CJ, Gilmore EM, Bolger C, Watkins CL, Hughes AM.

Br J Clin Pharmacol. 2004 Nov;58(5):470-5.

14.

An investigation of components of variance and tachyphylaxis in a placebo-controlled intravenous tyramine study.

Cantarini MV, Watkins CL, Growcott J, Hughes AM.

Br J Clin Pharmacol. 2004 May;57(5):657-60.

15.
16.

Effect of itraconazole on the pharmacokinetics of rosuvastatin.

Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV.

Clin Pharmacol Ther. 2003 Apr;73(4):322-9.

PMID:
12709722
17.

The effect of fluconazole on the pharmacokinetics of rosuvastatin.

Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV.

Eur J Clin Pharmacol. 2002 Nov;58(8):527-31. Epub 2002 Oct 3.

PMID:
12451430

Supplemental Content

Loading ...
Support Center